PURAPHARM：ANNOUNCEMENTOFFINALRESULTSFORTHEYEARENDED31DECEMBER2025.pdf

1、1Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia

2、nce upon the whole or any part of the contents of this announcement.PURAPHARM CORPORATION LIMITED培 力 農 本 方 有 限 公 司(Incorporated in the Cayman Islands with limited liability)(Stock code:1498)ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025FINANCIAL HIGHLIGHTSYear ended 31 December202

3、5%of2024%ofChangeHK$000totalHK$000totalHK$000%Revenue Hong Kong concentrated Chinese medicine granule192,31757.2%207,59154.3%(15,274)(7.4%)Chinese healthcare products92,55727.5%84,30222.1%8,2559.8%Nongs（農本方）Chinese medicine clinics51,23815.2%56,31314.7%(5,075)(9.0%)China concentrated Chinese medicin

4、e granule and plantation 10.1%33,8848.9%(33,883)(100%)336,113100%382,090100%(45,977)(12.0%)Gross profit180,156205,142(24,986)(12.2%)Net loss for the year(35,223)(35,439)2160.6%2The board(the“Board”)of directors(the“Directors”)of PuraPharm Corporation Limited(the“Company”)hereby presents the consolid

5、ated results of the Company and its subsidiaries(collectively referred to as the“Group”)for the year ended 31 December 2025(the“Reporting Period”)with the comparative audited figures for the year ended 31 December 2024 as follows.CONSOLIDATED STATEMENT OF PROFIT OR LOSSYear ended 31 December 2025202

6、52024NotesHK$000HK$000Revenue4336,113382,090Cost of sales(155,957)(176,948)Gross profit180,156205,142Other income and gains45,46517,391Selling and distribution expenses(52,484)(64,912)Administrative expenses(152,051)(159,474)Share of loss of a joint venture(88)(312)Impairment loss on property,plant